Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

CT-guided IRE therapy offers safe, feasible primary local treatment for advanced pancreatic cancer

A small group of patients with locally advanced unresectable pancreatic carcinoma suffered no major ill effects-pancreatitis or fistula formation-after undergoing percutaneous CT-guided irreversible electroporation (IRE)-a nonthermal ablation technology that is safe near vascular and ductal structures-as a therapy.

8 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna Breast Cancer Prognostic Gene Signature Assay for assessing a woman's 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

From NanoString Technologies 7 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.

6 May 2014

New biomarker shows promise in improving screening for esophageal cancer

A new biomarker for esophageal cancer shows promise in improving screening for this deadly disease and its precursor, Barrett's esophagus.

6 May 2014

$RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer$

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

2 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. In recognition of May's Skin Cancer Awareness Month and Melanoma Monday on May 5th, Mount Sinai Health System experts are arming the public with vital tips on prevention and offering FREE skin cancer screenings.

26 Apr 2014

Research team discovers new water-soluble fluorescent system for early detection of cancer cells

A research team lead by Academy Professor Kari Rissanen at the University of Jyväskylä has discovered a new water-soluble fluorescent detection system that is extremely sensitive to pyrophosphate (PPi).

25 Apr 2014

Researchers examine interaction between alcohol and tobacco in risk of ESCC

The rate of developing esophageal squamous cell carcinoma (ESCC) nearly doubles in those who both smoke and drink compared to those who only smoke or drink, according to new research published in The American Journal of Gastroenterology.

23 Apr 2014

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. T

23 Apr 2014

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Treating patients with nonmetastatic clear-cell renal cell carcinoma with the tyrosine kinase inhibitor axitinib could not only prevent disease progression, but also shrink tumours before surgery, show the results of a phase II trial.

22 Apr 2014

Surgery promising for non-metastatic RCC with thrombus

Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology.

22 Apr 2014

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.

22 Apr 2014

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.

22 Apr 2014

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.

22 Apr 2014

Carcinoma News and Research

Further Reading

CT-guided IRE therapy offers safe, feasible primary local treatment for advanced pancreatic cancer

ArQule reports net loss of $7,141,000 in first quarter 2014

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay

FDA accepts Merck's MK-3475 BLA for review

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Liver cancer screening in cirrhosis patients improves survival rates

New biomarker shows promise in improving screening for esophageal cancer

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Skin Cancer Awareness Month and Melanoma Monday: Mount Sinai experts to share vital skin cancer tips

Research team discovers new water-soluble fluorescent system for early detection of cancer cells

Researchers examine interaction between alcohol and tobacco in risk of ESCC

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Surgery promising for non-metastatic RCC with thrombus

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Multiple lines of targeted therapy extend life for mRCC patients

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News